Berenberg analyst Harry Gillis raised the firm’s price target on BioNTech (BNTX) to $155 from $150 and keeps a Buy rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech SE: Promising Clinical Trials and Strong Buy Rating Reinforced by Robert Burns
- BioNTech’s Promising Phase 2 Trial Results for Pumitamig in TNBC Justify Buy Rating
- FDA probe into COVID vaccines includes adults, Bloomberg reports
- FDA to investigate COVID vaccine safety across age groups
- BioNTech and BMS Report Promising Phase 2 Results for TNBC Treatment